Ixcela Inc

AVI BioPharma is a biopharmaceutical company that develops drugs to treat life-threatening diseases using its patented third generation antisense technology. It has completed clinical trials with its NeuGene antisense drugs in more than 300 subjects, addressing cardiovascular restenosis, infectious diseases, cancer, polycystic kidney disease and drug metabolism. Its most advanced cardiovascular program is for restenosis, where it has completed Phase II trials, evaluating its drug, Resten-NG. AVI BioPharma is also in a Phase II clinical trial with a drug for Hepatitis C infection and its influenza A drug candidate has been confirmed to have efficacy against avian influenza H5N1 in preclinical studies. AVI BioPharma maintains a location in Portland, Ore.

AutoGen is a leading provider of fully automated workflows for the isolation of nucleic acids, serving research and clinical laboratories across the United States and internationally. The company is committed to delivering personalized boutique-level service, offering high-quality extraction services, and a range of instruments and consumables tailored to meet diverse laboratory needs. With proven workflows designed to save time, labor, and costs, AutoGen equips labs with advanced technology for DNA and RNA extraction, including specialized platforms and kits. Their expertise ensures clients receive the highest quality nucleic acid for downstream applications, while their responsive customer service distinguishes them in the industry. Generated from the website